September 22, 2011 08:15 ET

Equity Research on Eli Lilly & Co. and Johnson & Johnson - Dividend-Paying Major Pharmaceuticals Attract Investors

NEW YORK, NY--(Marketwire - Sep 22, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Major industry and are offering free analytical research on Eli Lilly & Co. (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ). Register with us today at to have free access to these research reports.

As market volatility continues to scare many investors away from the stock market, some analysts are suggesting looking to major blue chip dividend-paying stocks. Some major drug manufacturers such as Eli Lilly & Co. and Johnson & Johnson have both been in business for well over 100 years - their decent returns and steady dividends throughout may be heartening to investors looking for lower volatility stocks. Eli Lilly & Co. and Johnson & Johnson reports are accessible for free by registering today at or is the Ultimate Trading Environment for investors. If you are considering owning Eli Lilly & Co. and Johnson & Johnson then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

It should be noted that while many major drug manufacturers may look appealing in this economic climate, the sector is not without its risks. Over the next several years, many of the patents on some of the world's best known prescription pharmaceuticals are set to expire. When these patents are gone, many major drug manufacturers will have to deal with stiff competition from cheaper generic versions of their drugs. Get your free reports on Eli Lilly & Co. and Johnson & Johnson at There is no commitment to join.

Companies in the sector are constantly looking to develop new patented drugs and new marketing techniques in order to counter the losses that are sure to come from their expired patents.

The two Drug Manufacturers - Major stocks research reports are available for free by signing up now on


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information